<DOC>
	<DOCNO>NCT01653912</DOCNO>
	<brief_summary>- Dose-finding study GSK2110183 administer combination carboplatin paclitaxel subject recurrent ovarian cancer . - Safety efficacy study GSK2110183 administer combination carboplatin paclitaxel subject platinum-resistant ovarian cancer .</brief_summary>
	<brief_title>Dose-finding Study Platinum-Resistant Ovarian Cancer</brief_title>
	<detailed_description>PKB116611 open-label Phase I/II study investigational drug GSK2110183 give combination carboplatin paclitaxel subject recurrent ovarian cancer . Phase I dose escalation evaluation daily oral dos GSK2110183 administer combination every 3 week carboplatin paclitaxel subject recurrent ovarian cancer . Phase II single arm evaluation clinical efficacy combination identify Phase I subject platinum-resistant ovarian cancer .</detailed_description>
	<mesh_term>Ovarian Neoplasms</mesh_term>
	<mesh_term>Paclitaxel</mesh_term>
	<mesh_term>Albumin-Bound Paclitaxel</mesh_term>
	<mesh_term>Carboplatin</mesh_term>
	<criteria>Phase I Female , 18 year age signing informed consent form , capable giving/complying write informed consent Histologically cytologically confirm serous ovarian cancer ( include primary peritoneal Fallopian tube ) Negative serum pregnancy test woman childbearing potential within 14 day first dose treatment , agree use effective contraception during/after ( 6 month post dose paclitaxel 30 day post dose GSK2110183 whichever longer ) Performance Status score 02 accord ECOG scale . Able swallow retain oral medication Subjects diagnose previously Type 2 diabetes must diagnose ≥ 6 month prior enrollment Prior treatmentrelated toxicity ( except alopecia ) must ≤ Grade 1 accord NCICTCAE ( Version 4.0 [ NCI , 2009 ] ) time treatment allocation OR ≤ Grade 2 stable 4 week long time screen evaluation . Exception : Subjects peripheral neuropathy &gt; /= Grade 2 NOT eligible Adequate organ system function Phase II Cohort A Phase I criteria Documented complete partial response RECIST least 1 prior platinumbased therapy Progression define either ( 1 ) RECIST v1.1 criterion ( 2 ) GCIG CA 125 criterion associate symptom necessitate treatment 1 6 month prior platinumbased therapy either adjuvant metastatic setting Subjects allow maximum one nonplatinumbased therapy onset platinum resistance Must radiologically measurable disease i.e . present least one measurable lesion per RECIST 1.1 Cohort B Phase I criteria Documented complete partial response RECIST least 1 prior platinumbased therapy Progression define either ( 1 ) RECIST v1.1 criterion ( 2 ) GCIG CA 125 criterion associate symptom necessitate treatment treat regimen contain carboplatin paclitaxel ( within 4 week complete treatment ) Subjects required start treatment within 8 week last infusion chemotherapy may anticancer therapy intervening time Must radiologically measurable disease i.e . present least one measurable lesion per RECIST 1.1 Additional restriction number prior therapy may add eligibility criterion base emerge data History another malignancy ( exception may apply ) Serious and/or unstable preexist medical psychiatric disorder , condition could interfere subject 's safety , obtain informed consent compliance study procedure Current use prohibit medication treatment . Chemotherapy , immunotherapy , anticancer therapy within 14 day prior first dose study drug Radiotherapy prior initiation therapy ( exception may apply ) Contraindications ( identify investigator ) dose carboplatin and/or paclitaxel History reduction standard care paclitaxel dose peripheral neuropathy No known immediate delay hypersensitivity reaction idiosyncratic reaction drug similar relate GSK2110183 No know delay hypersensitivity reaction idiosyncratic reaction drug similar carboplatin paclitaxel ( exception may apply ) Prior use drug target AKT include perifosine History Type 1 diabetes Gastrointestinal disease condition could affect absorption predispose subject gastrointestinal ulceration Mucosal internal bleeding Major surgery within last four week Infection require parenteral oral antiinfective treatment Severe uncontrolled systemic disease Brain metastasis and/or leptomeningeal disease QTcF interval ≥ 470 msec Bundle branch block , pacemaker clinically significant ECG abnormality include 2nd degree ( Type II ) 3rd degree atrioventricular ( AV ) block History myocardial infarction , acute coronary syndrome ( include unstable angina ) , coronary angioplasty , stenting bypass graft within six month Screening Class II , III IV heart failure define NYHA functional classification system Pregnant lactate female Malignancies relate HIV solid organ transplant ; history know HIV , history know HBV surface antigen positivity ( subject document laboratory evidence HBV clearance may enrol ) positive HCV antibody</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2014</verification_date>
	<keyword>cancer</keyword>
	<keyword>ovarian</keyword>
	<keyword>platinum-resistant</keyword>
</DOC>